Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Share-based Compensation: 2021-2025

Historic Share-based Compensation for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $20,205.

  • InMed Pharmaceuticals' Share-based Compensation fell 30.24% to $20,205 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,547, marking a year-over-year decrease of 21.87%. This contributed to the annual value of $119,307 for FY2025, which is 13.37% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Share-based Compensation stood at $20,205, which was down 24.41% from $26,729 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Share-based Compensation peaked at $214,779 during Q4 2021, and registered a low of $18,264 during Q4 2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Share-based Compensation value was $28,964 (recorded in 2024), while the average stood at $33,460.
  • Its Share-based Compensation has fluctuated over the past 5 years, first slumped by 78.41% in 2023, then rose by 26.80% in 2024.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Share-based Compensation stood at $214,779 in 2021, then slumped by 67.11% to $70,638 in 2022, then slumped by 74.14% to $18,264 in 2023, then rose by 26.80% to $23,159 in 2024, then slumped by 30.24% to $20,205 in 2025.
  • Its Share-based Compensation was $20,205 in Q3 2025, compared to $26,729 in Q2 2025 and $40,454 in Q1 2025.